History
Documents created during the development process.
Background information
-
-
TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: Appendix A - decision paper presented to the Institute's Guidance Executive
-
-
-
TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: Appendix A - provisional matrix of stakeholders
-
-
TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: Appendix B - GE Proposal Paper September 2013
-
-
-
Review decision - March 2008: table of comments
-
Review decision - March 2008: table of comments (PDF 135 KB)
-
-
TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: distribution list
-
-
People with chronic hepatitis C to benefit from guidance on new drugs and treatments information
-
People with chronic hepatitis C to benefit from guidance on new drugs and treatments (PDF 99 KB)
-
Health technology assessment: interferon alpha (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C
-
Final Appraisal Determination
Appraisal Consultation Document: Interferon alpha (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C
Health Technology Assessment: Interferon alpha (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C
-
Health Technology Assessment: Interferon alpha (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C
-
Protocol for Pegylated interferon alpha 2a and alpha 2b in the treatment of chronic hepatitis C
-
Protocol for Pegylated interferon alpha 2a and alpha 2b in the treatment of chronic hepatitis C
-